CD38 and Miyoshi myopathy: Anti-CD38 studies are rare due to several factors, including marked extratumoral toxicity due to CD38 receptor expression on normal hematopoietic cells, the availability of drugs (daratumomab, isatuximab) targeting this target, and the high risk of disease relapse in r/r MM due to reduced CD38 expression (85, 86).